Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
$8.69 0.27 (3.21%)
Market Cap: $1.19B
As of 08/15/22 12:35 PM EDT. Market open.
Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
$8.69 0.27 (3.21%)
Market Cap: $1.19B
As of 08/15/22 12:35 PM EDT. Market open.
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts ... read more
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Peter Greenleaf
Full Time Employees
294
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Peter Greenleaf
Full Time Employees
294
Address
1203-4464 Markham St, British Columbia, Victoria, V8Z 7X8.
PRICE CHART
From:
To:
NEWS
KEY STATS
Open
$8.36
Previous Close
$8.42
Days Range
$8.23 - $8.45
52 week range
$7.70 - $33.97
Volume
927,397
Avg. Volume (30 days)
3,104,797
Market Cap
$1.19B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
141,892,181
Open
$8.36
Previous Close
$8.42
Days Range
$8.23 - $8.45
52 week range
$7.70 - $33.97
Volume
927,397
Avg. Volume (30 days)
3,104,797
Market Cap
$1.19B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
141,892,181
Open in:
Open in:
INSIDER TRANSACTIONS FOR AURINIA PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Jayne David R.W. | Director | May 18, 2022 | Option Exercise | $3.62 | 10,000 | 36,200 | 40,000 | Jul 11, 2022, 06:16 AM |
| MacKay-Dunn R. Hector | Director | Mar 09, 2022 | Buy | $11.00 | 5,000 | 54,985 | 11,000 | Mar 11, 2022, 04:05 PM |
| MILNE GEORGE M JR | Director | Mar 04, 2022 | Buy | $10.82 | 5,000 | 54,100 | 50,000 | Mar 08, 2022, 04:06 PM |
| Martin Michael Robert | Chief Business Officer | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 59,512 | Mar 04, 2022, 04:13 PM |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | Mar 02, 2022 | Sale | $12.01 | 3,052 | 36,655 | 16,224 | Mar 04, 2022, 04:12 PM |
| Miller Joseph M | Chief Financial Officer | Mar 02, 2022 | Sale | $12.01 | 3,060 | 36,751 | 6,610 | Mar 04, 2022, 04:12 PM |
| Colao Massimilano | Chief Commercial Officer | Mar 02, 2022 | Sale | $12.01 | 3,205 | 38,492 | 13,495 | Mar 04, 2022, 04:11 PM |
| Greenleaf Peter | Chief Executive Officer | Mar 02, 2022 | Sale | $12.01 | 9,068 | 108,907 | 32,967 | Mar 04, 2022, 04:11 PM |
| Solomons Neil | Chief Medical Officer | Mar 02, 2022 | Sale | $12.01 | 4,846 | 58,200 | 90,953 | Mar 04, 2022, 04:10 PM |
| Huizinga Robert Bindert | EVP of Research | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 69,379 | Mar 04, 2022, 04:10 PM |
| Leversage Jill | Director | Dec 13, 2021 | Buy | $20.04 | 1,600 | 32,064 | 5,300 | Dec 15, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Option Exercise | $18.38 | 29,000 | 533,020 | 95,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 10, 2021 | Sale | $31.14 | 60,000 | 1,868,500 | 76,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 126,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Sale | $29.01 | 40,000 | 1,160,280 | 66,861 | Nov 12, 2021, 04:18 PM |
| Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Option Exercise | $5.83 | 100,000 | 583,200 | 187,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Option Exercise | $5.30 | 100,000 | 530,000 | 187,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 87,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Sale | $28.89 | 100,000 | 2,889,000 | 87,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Sale | $31.11 | 100,000 | 3,110,800 | 97,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Option Exercise | $5.30 | 45,000 | 238,500 | 182,299 | Nov 03, 2021, 04:24 PM |
| Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 137,299 | Nov 03, 2021, 04:24 PM |
| Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Option Exercise | $3.20 | 45,000 | 144,000 | 221,861 | Nov 03, 2021, 04:20 PM |
| Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 176,861 | Nov 03, 2021, 04:20 PM |
| Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Option Exercise | $3.20 | 95,000 | 304,000 | 195,728 | Oct 26, 2021, 04:33 PM |
| Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Sale | $29.75 | 130,000 | 3,867,500 | 65,728 | Oct 26, 2021, 04:33 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Option Exercise | $2.86 | 27,136 | 77,715 | 133,228 | Sep 22, 2021, 04:53 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Sale | $23.99 | 32,500 | 779,533 | 106,092 | Sep 22, 2021, 04:53 PM |
| Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Option Exercise | $7.40 | 87,500 | 647,750 | 264,361 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Option Exercise | $5.30 | 28,500 | 151,050 | 205,361 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Sale | $21.65 | 28,500 | 616,975 | 192,861 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Sale | $24.02 | 87,500 | 2,101,750 | 176,861 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $5.30 | 44,000 | 233,200 | 220,861 | Sep 16, 2021, 05:01 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.78 | 44,000 | 958,220 | 206,861 | Sep 16, 2021, 05:01 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $4.25 | 90,000 | 382,500 | 266,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 13, 2021 | Option Exercise | $5.30 | 25,000 | 132,500 | 201,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.19 | 90,000 | 1,907,217 | 176,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 10, 2021 | Sale | $19.80 | 25,000 | 495,000 | 176,861 | Sep 14, 2021, 06:16 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 14, 2021 | Sale | $21.75 | 22,500 | 489,375 | 106,092 | Sep 14, 2021, 05:12 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 10, 2021 | Sale | $19.80 | 10,000 | 197,950 | 133,592 | Sep 14, 2021, 05:12 PM |
| Solomons Neil | Chief Medical Officer | Sep 13, 2021 | Option Exercise | $3.20 | 150,000 | 480,000 | 287,299 | Sep 14, 2021, 05:11 PM |
| Solomons Neil | Chief Medical Officer | Sep 10, 2021 | Sale | $19.84 | 150,000 | 2,976,000 | 137,299 | Sep 14, 2021, 05:11 PM |
| Martin Michael Robert | Chief Business Officer | Sep 07, 2021 | Sale | $18.10 | 7,500 | 135,750 | 176,861 | Sep 08, 2021, 04:04 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 07, 2021 | Sale | $18.30 | 5,000 | 91,500 | 138,592 | Sep 08, 2021, 04:03 PM |
| Martin Michael Robert | Chief Business Officer | Aug 26, 2021 | Sale | $17.81 | 22,500 | 400,725 | 184,361 | Aug 27, 2021, 04:09 PM |
| Solomons Neil | Chief Medical Officer | Aug 25, 2021 | Sale | $15.85 | 5,000 | 79,250 | 137,299 | Aug 26, 2021, 04:15 PM |
| Solomons Neil | Chief Medical Officer | Aug 09, 2021 | Sale | $16.03 | 45,000 | 721,350 | 142,299 | Aug 10, 2021, 04:11 PM |
| Martin Michael Robert | Chief Business Officer | Aug 09, 2021 | Sale | $16.01 | 5,000 | 80,050 | 206,861 | Aug 10, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Jul 28, 2021 | Sale | $13.86 | 5,000 | 69,300 | 211,861 | Jul 29, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Jun 22, 2021 | Sale | $13.76 | 5,000 | 68,800 | 216,861 | Jun 23, 2021, 04:06 PM |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | May 11, 2021 | Buy | $10.07 | 9,900 | 99,739 | 9,900 | May 12, 2021, 04:34 PM |
| Greenleaf Peter | Chief Executive Officer | May 11, 2021 | Buy | $10.71 | 5,125 | 54,891 | 13,453 | May 12, 2021, 04:32 PM |
| Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Option Exercise | $3.02 | 40,000 | 120,800 | 227,299 | Mar 15, 2021, 04:36 PM |
| Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Sale | $13.49 | 40,000 | 539,600 | 187,299 | Mar 15, 2021, 04:36 PM |
| MILNE GEORGE M JR | Director | Mar 05, 2021 | Buy | $13.00 | 5,000 | 65,000 | 45,000 | Mar 09, 2021, 04:25 PM |
| Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 400 | 6,412 | 400 | Feb 02, 2021, 03:22 PM |
| Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 1,200 | 19,236 | 1,200 | Feb 02, 2021, 03:22 PM |
| Hayden Michael R | Director | Jan 29, 2021 | Option Exercise | $5.79 | 95,000 | 550,100 | 95,000 | Feb 02, 2021, 03:18 PM |
| Robertson Stephen P. | EVP, General Counsel | Jan 28, 2021 | Buy | $16.14 | 900 | 14,526 | 2,720 | Jan 29, 2021, 12:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Jayne David R.W. | Director | 05/18/2022 | 36,200 |
| MacKay-Dunn R. Hector | Director | 03/09/2022 | 54,985 |
| MILNE GEORGE M JR | Director | 03/04/2022 | 54,100 |
| Martin Michael Robert | Chief Business Officer | 03/02/2022 | 58,236 |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | 03/02/2022 | 36,655 |
| Miller Joseph M | Chief Financial Officer | 03/02/2022 | 36,751 |
| Colao Massimilano | Chief Commercial Officer | 03/02/2022 | 38,492 |
| Greenleaf Peter | Chief Executive Officer | 03/02/2022 | 108,907 |
| Solomons Neil | Chief Medical Officer | 03/02/2022 | 58,200 |
| Huizinga Robert Bindert | EVP of Research | 03/02/2022 | 58,236 |
| Leversage Jill | Director | 12/13/2021 | 32,064 |
| Martin Michael Robert | Chief Business Officer | 11/11/2021 | 533,020 |
| Martin Michael Robert | Chief Business Officer | 11/10/2021 | 1,868,500 |
| Martin Michael Robert | Chief Business Officer | 11/09/2021 | 1,508,500 |
| Martin Michael Robert | Chief Business Officer | 11/11/2021 | 1,160,280 |
| Solomons Neil | Chief Medical Officer | 11/10/2021 | 583,200 |
| Solomons Neil | Chief Medical Officer | 11/11/2021 | 530,000 |
| Solomons Neil | Chief Medical Officer | 11/09/2021 | 1,508,500 |
| Solomons Neil | Chief Medical Officer | 11/11/2021 | 2,889,000 |
| Solomons Neil | Chief Medical Officer | 11/10/2021 | 3,110,800 |
| Solomons Neil | Chief Medical Officer | 11/01/2021 | 238,500 |
| Solomons Neil | Chief Medical Officer | 11/01/2021 | 1,423,800 |
| Martin Michael Robert | Chief Business Officer | 11/01/2021 | 144,000 |
| Martin Michael Robert | Chief Business Officer | 11/01/2021 | 1,423,800 |
| Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 304,000 |
| Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 3,867,500 |
| Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 77,715 |
| Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 779,533 |
| Martin Michael Robert | Chief Business Officer | 09/21/2021 | 647,750 |
| Martin Michael Robert | Chief Business Officer | 09/20/2021 | 151,050 |
| Martin Michael Robert | Chief Business Officer | 09/20/2021 | 616,975 |
| Martin Michael Robert | Chief Business Officer | 09/21/2021 | 2,101,750 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 233,200 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 958,220 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 382,500 |
| Martin Michael Robert | Chief Business Officer | 09/13/2021 | 132,500 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 1,907,217 |
| Martin Michael Robert | Chief Business Officer | 09/10/2021 | 495,000 |
| Huizinga Robert Bindert | EVP of Research | 09/14/2021 | 489,375 |
| Huizinga Robert Bindert | EVP of Research | 09/10/2021 | 197,950 |
| Solomons Neil | Chief Medical Officer | 09/13/2021 | 480,000 |
| Solomons Neil | Chief Medical Officer | 09/10/2021 | 2,976,000 |
| Martin Michael Robert | Chief Business Officer | 09/07/2021 | 135,750 |
| Huizinga Robert Bindert | EVP of Research | 09/07/2021 | 91,500 |
| Martin Michael Robert | Chief Business Officer | 08/26/2021 | 400,725 |
| Solomons Neil | Chief Medical Officer | 08/25/2021 | 79,250 |
| Solomons Neil | Chief Medical Officer | 08/09/2021 | 721,350 |
| Martin Michael Robert | Chief Business Officer | 08/09/2021 | 80,050 |
| Martin Michael Robert | Chief Business Officer | 07/28/2021 | 69,300 |
| Martin Michael Robert | Chief Business Officer | 06/22/2021 | 68,800 |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | 05/11/2021 | 99,739 |
| Greenleaf Peter | Chief Executive Officer | 05/11/2021 | 54,891 |
| Solomons Neil | Chief Medical Officer | 03/12/2021 | 120,800 |
| Solomons Neil | Chief Medical Officer | 03/12/2021 | 539,600 |
| MILNE GEORGE M JR | Director | 03/05/2021 | 65,000 |
| Leversage Jill | Director | 01/29/2021 | 6,412 |
| Leversage Jill | Director | 01/29/2021 | 19,236 |
| Hayden Michael R | Director | 01/29/2021 | 550,100 |
| Robertson Stephen P. | EVP, General Counsel | 01/28/2021 | 14,526 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Load More
Period of Report: 06/30/2022
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2022
0.04%
1Q
12/31/2021
9.56%
2Q
09/30/2021
10.66%
3Q
06/30/2021
10.89%
4Q
03/31/2021
11.25%
5Q
Load More